During last night’s earnings call, Chromadex CEO Rob Fried discussed the results of recent clinical trials using NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes). Here’s what he said:
Category: PAD
In a recent interview, Northwestern’s Dr. Mary McDermott discussed key findings from her team’s randomized clinical trial investigating whether NAD+ booster Nicotinamide Riboside “NR” (FAQs) (Anecdotes) can enhance walking performance in patients with peripheral artery disease (PAD). The results (using 1000 mg NR) showed that NR significantly improved six-minute walking distance and treadmill walking time in PAD patients. A transcript and video of Dr. McDermott’s interview below: